{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:06:55Z","timestamp":1785416815703,"version":"3.56.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T00:00:00Z","timestamp":1679011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T00:00:00Z","timestamp":1679011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1038\/s41375-023-01869-1","type":"journal-article","created":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T11:03:03Z","timestamp":1679050983000},"page":"1554-1557","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Evaluation of bleeding events in patients receiving acalabrutinib therapy"],"prefix":"10.1038","volume":"37","author":[{"given":"Pooja S.","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Wiczer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6121-0082","authenticated-orcid":false,"given":"Lindsay","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur J.","family":"Pollauf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilly","family":"Palettas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leylah","family":"Azali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema A.","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Grever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry A.","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3403-9144","authenticated-orcid":false,"given":"Jennifer A.","family":"Woyach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4891-6144","authenticated-orcid":false,"given":"Adam S.","family":"Kittai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,17]]},"reference":[{"key":"1869_CR1","unstructured":"Calquence [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2022."},{"key":"1869_CR2","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1509981","volume":"374","author":"JC Byrd","year":"2016","unstructured":"Byrd JC, Harrington B, O\u2019Brien S, Jones JA, Schuh A, Devereux S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N. Engl J Med. 2016;374:323\u201332.","journal-title":"N. Engl J Med"},{"key":"1869_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-016-0250-9","volume":"9","author":"J Wu","year":"2016","unstructured":"Wu J, Zhang M, Liu D. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. J Hematol Oncol. 2016;9:1\u20134.","journal-title":"J Hematol Oncol"},{"key":"1869_CR4","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1182\/bloodadvances.2017011999","volume":"1","author":"AP Bye","year":"2017","unstructured":"Bye AP, Unsworth AJ, Desborough MJ, Hildyard CAT, Appleby N, Bruce D, et al. Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib. Blood Adv. 2017;1:2610\u201323.","journal-title":"Blood Adv"},{"key":"1869_CR5","doi-asserted-by":"crossref","unstructured":"Byrd JC, Hillmen P, Ghia P, Kater AP, Chanan-Khan A, Furman RR, et al., editors. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial 2021: American Society of Clinical Oncology (ASCO).","DOI":"10.1200\/JCO.21.01210"},{"key":"1869_CR6","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1182\/blood.2018884940","volume":"135","author":"JC Byrd","year":"2020","unstructured":"Byrd JC, Wierda WG, Schuh A, Devereux S, Chaves JM, Brown JR, et al. Acalabrutinib monotherapy in patients with relapsed\/refractory chronic lymphocytic leukemia: updated phase 2 results. Blood 2020;135:1204\u201313.","journal-title":"Blood"},{"key":"1869_CR7","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1182\/bloodadvances.2018030007","volume":"3","author":"FT Awan","year":"2019","unstructured":"Awan FT, Schuh A, Brown JR, Furman RR, Pagel JM, Hillmen P, et al. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood Adv. 2019;3:1553\u201362.","journal-title":"Blood Adv"},{"key":"1869_CR8","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","volume":"391","author":"M Wang","year":"2018","unstructured":"Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018;391:659\u201367.","journal-title":"Lancet"},{"key":"1869_CR9","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","volume":"395","author":"JP Sharman","year":"2020","unstructured":"Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395:1278\u201391.","journal-title":"Lancet"},{"key":"1869_CR10","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","volume":"8","author":"S Schulman","year":"2010","unstructured":"Schulman S, Anger\u00e5s U, Bergqvist D, Eriksson B, Lassen M, Fisher W, et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost. 2010;8:202\u20134.","journal-title":"J Thromb Haemost"},{"key":"1869_CR11","unstructured":"Health UDo, Services H. Common terminology criteria for adverse events v. 5.0. 2017."},{"key":"1869_CR12","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.1038\/s41375-021-01252-y","volume":"35","author":"RR Furman","year":"2021","unstructured":"Furman RR, Byrd JC, Owen RG, O\u2019Brien SM, Brown JR, Hillmen P, et al. Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. Leukemia 2021;35:3201\u201311.","journal-title":"Leukemia"},{"key":"1869_CR13","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/jth.13651","volume":"15","author":"JJ Shatzel","year":"2017","unstructured":"Shatzel JJ, Olson SR, Tao DL, McCarty OJ, Danilov AV, DeLoughery TG. Ibrutinib\u2010associated bleeding: pathogenesis, management and risk reduction strategies. J Thromb Haemost. 2017;15:835\u201347.","journal-title":"J Thromb Haemost"},{"key":"1869_CR14","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.3324\/haematol.2018.207183","volume":"104","author":"J Series","year":"2019","unstructured":"Series J, Garcia C, Levade M, Viaud J, Si\u00e9 P, Ysebaert L, et al. Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions. Haematologica 2019;104:2292.","journal-title":"Haematologica"}],"updated-by":[{"DOI":"10.1038\/s41375-023-01927-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000}}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01869-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01869-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01869-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T14:02:35Z","timestamp":1688392955000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01869-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,17]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["1869"],"URL":"https:\/\/doi.org\/10.1038\/s41375-023-01869-1","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41375-023-01927-8","asserted-by":"object"}]},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,17]]},"assertion":[{"value":"27 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2023","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41375-023-01927-8","URL":"https:\/\/doi.org\/10.1038\/s41375-023-01927-8","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PSK, TW, LR, AJP, AZ, MP, LA have no conflicts to disclose. SAB receives research funding from AstraZeneca, and has consulted for Pharmacyclics, Janssen, Beigene, and AstraZeneca, and has received honorarium from OncLive, and has received travel funding from Arqule. JCB has consulted for Syndax, Trillium, AstraZeneca, Novartis, Newave and Kronos, and is the chair of the scientific advisory board and a major stockholder in Vincerx Pharma. MRG receives research funding from the Hairy Cell Leukemia Foundation for Patient Data Registry, has consulted AstraZeneca, Pharmacyclics, Ascerta (participant in long-term follow-up Data Safety Monitoring Committee), Axio, Inc; Serono\/Merck, has received travel expenses from the Hairy Cell Leukemia Foundation, is the scientific board chair for the Hairy Cell Leukemia Foundation Scientific Board (no reimbursement), and has received scientific honorarium from the University of Pittsburgh. KAR receives research funding from Genentech, AbbVie, Janssen, and Novartis, consults for AbbVie, AstraZeneca, Genentech, Pharmacyclics, Innate Pharma, and Beigene, and received travel funding from AstraZeneca. JAW has received research funding from Janssen, Morphosys, and Schrodinger and has consulted for Abbvie, AstraZeneca, Beigene, Genentech, Janssen, Loxo, Newave, and Pharmacyclics. ASK has received research funding from AstraZeneca, and has consulted for Abbvie, AstraZeneca, Beigene, KITE, and Janssen.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}